New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLL-37 vs PT-141 (Bremelanotide)

LL-37 vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Immune SupportRecovery & Repair
LL-37
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
LL-37 is the only known human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and viruses by disrupting their membranes, while simultaneously modulating immune responses. Used for antimicrobial protection, immune priming, and wound healing.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
2–3 hours
Admin Route
SubQ, Topical, Intranasal
SubQ
Research
Typical Dose
100–300 mcg
0.5–1.75 mg
Frequency
2–3x per week
As needed (not daily)
Key Benefits
  • Broad-spectrum antimicrobial (bacteria, fungi, viruses)
  • Promotes wound healing and angiogenesis
  • Immune system modulation — enhances innate immunity
  • Reduces LPS-mediated endotoxemia
  • Anti-biofilm activity against resistant organisms
  • Promotes tissue regeneration and keratinocyte migration
  • May protect against sepsis
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Injection site redness and irritation
  • Mild inflammatory response at injection site
  • Potential pro-inflammatory at high doses
  • Rare: fever or flu-like symptoms at initiation
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With